Evidence map›Paper›PMID 30386047›Full record

ReviewIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India

Liver Functional Volumetry by Tc-99m Mebrofenin Hepatobiliary Scintigraphy before Major Liver Resection: A Game Changer.

Manoj Gupta, Partha Sarathi Choudhury, Shivendra Singh, Dibyamohan Hazarika

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05280990 (HepaRAS Trial), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05280990 nawithdrawnnot on this map

HepaRAS Trial: Changes in Hepatectomy Risk Assessment When Incorporating Mebrofenin HIDA for Functional Evaluation of the Liver Remnant: A Pilot Study

TypeinterventionalSponsorBoris Gala LopezRan2023 to 2025Enrolled0ConditionsLiver Failure as A Complication of Care, 30-day MortalityArmsmHBS, CT/MRI volumetry
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Molecular pharmaceutics · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Liver Resection for Hepatocellular Carcinoma: Recent Advances.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Manoj GuptaDepartment of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Partha Sarathi ChoudhuryDepartment of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Shivendra SinghDepartment of GI and HPB Oncosurgery, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Dibyamohan HazarikaDepartment of Radiology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Rajiv Gandhi Cancer Institute and Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Future remnant liver function (FRL-F) estimation is important before major liver resection to avoid posthepatectomy liver failure (PHLF). Conventionally, it is estimated by global dynamic liver function tests which assume homogeneous liver function and unable to calculate regional function. Computed tomography is another method to estimate FRL volume but assumes that volume is equivalent to function. Hence, a global and regional non-invasive liver function test is desirable. Studies were identified by MEDLINE, PubMed, and Google Scholar for articles from January 1990 to December 2017 using the following keywords "Mebrofenin, hepatobiliary scintigraphy (HBS), FRL-F, PHLF, portal vein embolization (PVE)." HBS with technetium-99 m galactosyl human serum albumin (Tc-99m GSA) and Tc-99m Mebrofenin is a known test for functional liver assessment. Restricted availability of Tc-99m GSA only in Japan is a main drawback for its global acceptance. However, Tc-99m Mebrofenin is routinely available to the rest of the world. A unique protocol for FRL-F estimation by Tc-99m Mebrofenin is described in detail in this review. Tc-99m Mebrofenin HBS has shown a strong correlation to 15 min indocyanine green clearance. HBS has been reported better in predicting the risk of PHLF with a 2.69%/min/m

Indexed as

Future remnant liver functiongadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid magnetic resonance imaginghepatobiliary scintigraphymebrofeninportal vein embolizationposthepatectomy liver failure

Identifiers

PMID30386047
PMCPMC6194760
OpenAlexW2896473047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.